Irene Urbino
YOU?
Author Swipe
View article: Breast Isolated FLT3 Positive AML Relapse Treated with Gilteritinib in Monotherapy: Long- Term Follow-Up and Review of the Literature
Breast Isolated FLT3 Positive AML Relapse Treated with Gilteritinib in Monotherapy: Long- Term Follow-Up and Review of the Literature Open
Extramedullary relapse of acute myeloid leukemia (AML) is a relatively common occurrence, with the FMS-like tyrosine kinase 3 (FLT3) mutation being a significant risk factor. While gilteritinib is approved for treating relapsed/refractory …
View article: Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission
Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission Open
View article: Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia
Life-threatening complications and intensive care unit management in patients treated with blinatumomab for B-cell acute lymphoblastic leukemia Open
Blinatumomab, a CD3/CD19 bispecific antibody categorized under BiTEs (bispecific T-cell engagers), has recently gained approval as a standard of care in B-cell acute lymphoblastic leukemia (B-ALL) [1,2].Despite its efficacy, the emergence …
View article: P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML
P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML Open
Background: The Italian AML1718 trial (NCT03455504) investigating the safety and efficacy of the BCL-2 inhibitor venetoclax (VEN) in combination with Intensive fludarabine-based induction (FLAI) [fludarabine 30 mg/sqm from day 1 to day 5, …
View article: P678: EARLY WARNING RESPONSES IN CML PATIENTS: A REAL-LIFE TURIN EXPERIENCE
P678: EARLY WARNING RESPONSES IN CML PATIENTS: A REAL-LIFE TURIN EXPERIENCE Open
Background: In the last decades, tyrosine kinase inhibitors (TKI) have not only improved biological responses, but also survival and quality of life of chronic myeloid leukemia (CML) patients. In the large registration studies, results are…
View article: PB2057: THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY.
PB2057: THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY. Open
Topic: 12. Bone marrow failure syndromes incl. PNH - Clinical Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease characterized by chronic hemolysis, bone marrow failure and increased risk of thrombosis. PNH is frequent…
View article: Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors
Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors Open
An accurate estimation of AML prognosis is complex since it depends on patient-related factors, AML manifestations at diagnosis, and disease genetics. Furthermore, the depth of response, evaluated using the level of MRD, has been establish…
View article: Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience Open
In the present study, we aimed to evaluate the absolute risk of infection in the real-life setting of AML patients treated with CPX-351. The study included all patients with AML from 30 Italian hematology centers of the SEIFEM group who re…
View article: Levofloxacin prophylaxis omission in acute myeloid leukemia during post induction aplasia: a single center study
Levofloxacin prophylaxis omission in acute myeloid leukemia during post induction aplasia: a single center study Open
Background and objectives: acute myeloid leukemia (AML) patients are at high risk of infections during post induction neutropenia. Recently, the role of antibacterial prophylaxis has been reconsidered due to concerns about the emergence …
View article: ECULIZUMAB DOSE ADJUSTMENTS DURING PREGNANCIES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A SINGLE CENTER EXPERIENCE.
ECULIZUMAB DOSE ADJUSTMENTS DURING PREGNANCIES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A SINGLE CENTER EXPERIENCE. Open
View article: P374: BLINATUMOMAB AS CONSOLIDATION FOR ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. A REAL-WORLD STUDY
P374: BLINATUMOMAB AS CONSOLIDATION FOR ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. A REAL-WORLD STUDY Open
Background: Blinatumomab is a CD3/CD19 bispecific T-cell engager approved for the treatment of relapsed/refractory (R/R) or minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (B-ALL). Recent phase 3 studi…
View article: Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021
Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021 Open
Acute myeloid leukemia (AML) in older patients is characterized by unfavorable prognosis due to adverse disease features and a high rate of treatment-related complications. Classical therapeutic options range from intensive chemotherapy in…
View article: Polycythemia Vera (PV): Update on Emerging Treatment Options
Polycythemia Vera (PV): Update on Emerging Treatment Options Open
Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by exuberant red cell production leading to a broad range of symptoms that compromise quality of life and productivity of patients. PV reduces survival expectati…
View article: Myeloid Neoplasms with Eosinophilia: Rare Entities with Emerging Diagnostic and Therapeutic Challenges
Myeloid Neoplasms with Eosinophilia: Rare Entities with Emerging Diagnostic and Therapeutic Challenges Open